Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress.

Bepirovirsen, a 20-mer ASO, has already entered phase III clinicalevaluation using the optimal dosing regimen of 300 mg subcutaneousinjection weekly for 24 weeks in nucleoside analogue-treatedHBeAg-negative non-cirrhotic patients with low (<3000 IU/mL)baseline HBsAg. The durability and long-term clinical outcomes amongbepirovirsen responders will need to be evaluated. The stop-to-cureapproach in those reaching HBsAg < 100 IU/mL should also beexplored. In the long run, bepirovirsen has the potential tofacilitate viral hepatitis elimination.